CCL5 and breast carcinoma: For example, HSF1 impairs immune responses in breast cancer by inhibiting CCL5-mediated CD8 + T cell infiltration [34], and CCL5 is recognized as a promising biomarker to guide immunotherapy in ovarian cancer [35].